Cantley Lewis Clayton Jr. - Net Worth and Insider Trading

Cantley Lewis Clayton Jr. Net Worth

The estimated net worth of Cantley Lewis Clayton Jr. is at least $12 Million dollars as of 2024-11-13. Cantley Lewis Clayton Jr. is the Director of Agios Pharmaceuticals Inc and owns about 200,596 shares of Agios Pharmaceuticals Inc (AGIO) stock worth over $12 Million. Details can be seen in Cantley Lewis Clayton Jr.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Cantley Lewis Clayton Jr. has not made any transactions after 2017-12-07 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Cantley Lewis Clayton Jr.

Cantley Lewis Clayton Jr. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Cantley Lewis Clayton Jr. owns 1 companies in total, including Agios Pharmaceuticals Inc (AGIO) .

Click here to see the complete history of Cantley Lewis Clayton Jr.’s form 4 insider trades.

Insider Ownership Summary of Cantley Lewis Clayton Jr.

Ticker	Comapny	Transaction Date	Type of Owner
AGIO	Agios Pharmaceuticals Inc	2017-12-07	director & 10 percent owner

Cantley Lewis Clayton Jr. Latest Holdings Summary

Cantley Lewis Clayton Jr. currently owns a total of 1 stock. Cantley Lewis Clayton Jr. owns 200,596 shares of Agios Pharmaceuticals Inc (AGIO) as of December 7, 2017, with a value of $12 Million.

Latest Holdings of Cantley Lewis Clayton Jr.

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
AGIO	Agios Pharmaceuticals Inc	2017-12-07	200,596	59.02	11,839,176

Holding Weightings of Cantley Lewis Clayton Jr.

Cantley Lewis Clayton Jr. Form 4 Trading Tracker

According to the SEC Form 4 filings, Cantley Lewis Clayton Jr. has made a total of 0 transactions in Agios Pharmaceuticals Inc (AGIO) over the past 5 years. The most-recent trade in Agios Pharmaceuticals Inc is the sale of 3,838 shares on December 7, 2017, which brought Cantley Lewis Clayton Jr. around $227,862.

Insider Trading History of Cantley Lewis Clayton Jr.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Cantley Lewis Clayton Jr. Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Cantley Lewis Clayton Jr. Ownership Network

Ownership Network List of Cantley Lewis Clayton Jr.

No Data

Ownership Network Relation of Cantley Lewis Clayton Jr.

Cantley Lewis Clayton Jr. Owned Company Details

What does Agios Pharmaceuticals Inc do?

Who are the key executives at Agios Pharmaceuticals Inc?

Cantley Lewis Clayton Jr. is the director & 10 percent owner of Agios Pharmaceuticals Inc. Other key executives at Agios Pharmaceuticals Inc include Chief Financial Officer Cecilia Jones , director & Chief Executive Officer Brian Goff , and Chief Medical Officer Sarah Gheuens .

Agios Pharmaceuticals Inc (AGIO) Insider Trades Summary

Over the past 18 months, Cantley Lewis Clayton Jr. made no insider transaction in Agios Pharmaceuticals Inc (AGIO). Other recent insider transactions involving Agios Pharmaceuticals Inc (AGIO) include a net sale of 9,416 shares made by Washburn Theodore James Jr. , a net sale of 64,534 shares made by Brian Goff , and a net sale of 14,160 shares made by James William Burns .

In summary, during the past 3 months, insiders sold 2,542 shares of Agios Pharmaceuticals Inc (AGIO) in total and bought 0 shares, with a net sale of 2,542 shares. During the past 18 months, 252,596 shares of Agios Pharmaceuticals Inc (AGIO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 252,596 shares.

Agios Pharmaceuticals Inc (AGIO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Agios Pharmaceuticals Inc Insider Transactions

No Available Data

Cantley Lewis Clayton Jr. Mailing Address

Above is the net worth, insider trading, and ownership report for Cantley Lewis Clayton Jr.. You might contact Cantley Lewis Clayton Jr. via mailing address: C/o Agios Pharmaceuticals, Inc., 38 Sidney Street, 2nd Floor, Cambridge Ma 02139.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.